GSK Highlights the P-III (RUBY) Trial Results of Jemperli to Treat Endometrial Cancer at Society of Gynecologic Oncology 2024
Shots:
- The P-III (RUBY) study assesses Jemperli + CT (carboplatin-paclitaxel) followed by Jemperli vs PBO (part 1) and Jemperli + CT followed by Jemperli + Zejula as maintenance therapy vs PBO (part 2) to treat primary advanced/recurrent endometrial cancer
- In the overall population, a 31% reduced death risk with a 16.4mos. mOS improvement (44.6mos. vs 28.2mos.) was seen in part 1 & a 40% reduced disease progression or death risk with a 6.2mos. mPFS improvement (14.5mos. vs 8.3mos.) was seen in part 2
- In the MMRp/MSS population, a trend in reduced risk of death by 21% with a 7mos. mOS improvement (34mos. vs 27mos.) was seen in part 1 & a 37% reduced disease progression or death risk with a 6mos. mPFS improvement (14.3mos. vs 8.3mos.) was seen in part 2
Ref: GSK | Image: GSK
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
